Featured Research

from universities, journals, and other organizations

New Drug Delivery System For Treating Cancer Tested In Animals

Date:
December 15, 2004
Source:
Johns Hopkins Medical Institutions
Summary:
Johns Hopkins researchers led by Jean Geschwind, M.D., associate professor of radiology and radiological science, are testing a novel method for delivering chemotherapeutic agents directly into liver tumors.

Johns Hopkins researchers led by Jean Geschwind, M.D., associate professor of radiology and radiological science, are testing a novel method for delivering chemotherapeutic agents directly into liver tumors.

In the study, catheters were inserted into the femoral artery of rabbits, and tiny beads, impregnated with the anticancer drug doxorubicin, were injected into the tumors. Control animals received intra-arterial injections of the drug alone. Plasma and tissue concentrations of doxorubicin were measured at 1, 12 and 24 hours and 3, 7 and 14 days following treatment.

In the animals treated with the doxorubicin-eluting beads, the concentration of doxorubicin within the tumor was greatest in the 7-day group, followed by the 3-day group, and remained high in the 14-day group, suggesting continuous emission of doxorubicin from the beads. In contrast, the plasma concentrations of the drug were low at all time points, indicating high retention of doxorubicin within the tumor and a lessening risk of systemic toxicity.

The greatest degree of tumor destruction was seen in the 7- to 14-day group. In contrast, control animals had markedly high plasma concentrations of the drug and low concentration of the agent in the tumor, which washed out of the tumor within an hour.

Due to its reduced systemic toxicity and greater tumor-killing efficacy, the researchers say the technique offers a potentially effective new approach to treating certain tumors in humans.


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins Medical Institutions. "New Drug Delivery System For Treating Cancer Tested In Animals." ScienceDaily. ScienceDaily, 15 December 2004. <www.sciencedaily.com/releases/2004/12/041208083740.htm>.
Johns Hopkins Medical Institutions. (2004, December 15). New Drug Delivery System For Treating Cancer Tested In Animals. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2004/12/041208083740.htm
Johns Hopkins Medical Institutions. "New Drug Delivery System For Treating Cancer Tested In Animals." ScienceDaily. www.sciencedaily.com/releases/2004/12/041208083740.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins